Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Period	TotalRevenue
2020-12-31	$6.79M
2021-12-31	$9.33M
2022-12-31	$9.22M
2023-12-31	$9.56M
2024-12-31	$10.90M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$13.72	+0.15%	0.22M
3
4
5

Avidity Biosciences Inc. (RNA) Revenue History

Revenue Data

Get Avidity Biosciences Inc. Data in Excel

More RNA Financial Data